13.71 USD
+0.38 (+2.85%)
13.98 USD
+0.27 (+1.97%)
AMRX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AMRX has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMRX.
1. Profitability
1.1 Basic Checks
- AMRX had positive earnings in the past year.
- In the past year AMRX had a positive cash flow from operations.
- In multiple years AMRX reported negative net income over the last 5 years.
- Each year in the past 5 years AMRX had a positive operating cash flow.
1.2 Ratios
- AMRX has a Return On Assets of 0.16%. This is in the better half of the industry: AMRX outperforms 77.49% of its industry peers.
- AMRX's Return On Invested Capital of 10.43% is amongst the best of the industry. AMRX outperforms 89.53% of its industry peers.
- AMRX had an Average Return On Invested Capital over the past 3 years of 7.98%. This is below the industry average of 12.84%.
- The last Return On Invested Capital (10.43%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROIC | 10.43% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
1.3 Margins
- The Profit Margin of AMRX (0.20%) is better than 77.49% of its industry peers.
- Looking at the Operating Margin, with a value of 12.32%, AMRX belongs to the top of the industry, outperforming 85.34% of the companies in the same industry.
- AMRX's Operating Margin has improved in the last couple of years.
- AMRX has a better Gross Margin (36.76%) than 60.21% of its industry peers.
- AMRX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% |
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMRX is still creating some value.
- The number of shares outstanding for AMRX has been reduced compared to 1 year ago.
- Compared to 5 years ago, AMRX has more shares outstanding
- Compared to 1 year ago, AMRX has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 1.93 indicates that AMRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- AMRX has a Altman-Z score (1.93) which is comparable to the rest of the industry.
- AMRX has a debt to FCF ratio of 11.13. This is a negative value and a sign of low solvency as AMRX would need 11.13 years to pay back of all of its debts.
- AMRX has a better Debt to FCF ratio (11.13) than 78.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Altman-Z | 1.93 |
ROIC/WACC1
WACC10.4%
2.3 Liquidity
- AMRX has a Current Ratio of 2.13. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
- AMRX has a Current ratio of 2.13. This is in the lower half of the industry: AMRX underperforms 60.21% of its industry peers.
- A Quick Ratio of 1.42 indicates that AMRX should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.42, AMRX is not doing good in the industry: 65.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 25.00% over the past year.
- The Earnings Per Share has been growing by 10.63% on average over the past years. This is quite good.
- The Revenue has grown by 16.73% in the past year. This is quite good.
- Measured over the past years, AMRX shows a quite strong growth in Revenue. The Revenue has been growing by 11.43% on average per year.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
3.2 Future
- The Earnings Per Share is expected to grow by 11.95% on average over the next years. This is quite good.
- The Revenue is expected to grow by 0.60% on average over the next years.
EPS Next Y40.43%
EPS Next 2Y27.65%
EPS Next 3Y26.98%
EPS Next 5Y11.95%
Revenue Next Year8.74%
Revenue Next 2Y7.7%
Revenue Next 3Y7.95%
Revenue Next 5Y0.6%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 18.28, which indicates a rather expensive current valuation of AMRX.
- AMRX's Price/Earnings ratio is rather cheap when compared to the industry. AMRX is cheaper than 83.25% of the companies in the same industry.
- AMRX is valuated rather cheaply when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 14.51 indicates a correct valuation of AMRX.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 83.77% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.30. AMRX is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.28 | ||
| Fwd PE | 14.51 |
4.2 Price Multiples
- AMRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMRX is cheaper than 85.86% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, AMRX is valued cheaper than 85.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.22 | ||
| EV/EBITDA | 11 |
4.3 Compensation for Growth
- AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of AMRX may justify a higher PE ratio.
- A more expensive valuation may be justified as AMRX's earnings are expected to grow with 26.98% in the coming years.
PEG (NY)0.45
PEG (5Y)1.72
EPS Next 2Y27.65%
EPS Next 3Y26.98%
5. Dividend
5.1 Amount
- No dividends for AMRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
13.71
+0.38 (+2.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-27 2026-02-27/bmo
Inst Owners45.17%
Inst Owner Change1.88%
Ins Owners46.29%
Ins Owner Change-4.23%
Market Cap4.31B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts81.82
Price Target14.79 (7.88%)
Short Float %4.39%
Short Ratio3.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)8.75%
PT rev (3m)20.83%
EPS NQ rev (1m)-1.1%
EPS NQ rev (3m)11.14%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)4.04%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.28 | ||
| Fwd PE | 14.51 | ||
| P/S | 1.47 | ||
| P/FCF | 18.22 | ||
| P/OCF | 13.15 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 11 |
EPS(TTM)0.75
EY5.47%
EPS(NY)0.95
Fwd EY6.89%
FCF(TTM)0.75
FCFY5.49%
OCF(TTM)1.04
OCFY7.6%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)0.45
PEG (5Y)1.72
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROCE | 13.2% | ||
| ROIC | 10.43% | ||
| ROICexc | 11.26% | ||
| ROICexgc | 21.11% | ||
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% | ||
| FCFM | 8.06% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Debt/EBITDA | 4.36 | ||
| Cap/Depr | 37.95% | ||
| Cap/Sales | 3.11% | ||
| Interest Coverage | 1.67 | ||
| Cash Conversion | 54.45% | ||
| Profit Quality | 4008.53% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 1.93 |
F-Score7
WACC10.4%
ROIC/WACC1
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y40.43%
EPS Next 2Y27.65%
EPS Next 3Y26.98%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.74%
Revenue Next 2Y7.7%
Revenue Next 3Y7.95%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year14%
EBIT Next 3Y11.66%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status for AMRX stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.
How financially healthy is AMNEAL PHARMACEUTICALS INC?
The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 4 / 10.
Can you provide the expected EPS growth for AMRX stock?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 40.43% in the next year.